Restricted accessResearch articleFirst published online 2025-9
The global,regional,and national burden and attributable risk factors of Alzheimer's disease and other dementias,1990-2021: A systematic analysis for the Global Burden of Disease Study
Dementia is a syndrome characterized by a decline in cognitive function, with Alzheimer's disease (AD) being the most common type. Updated global statistics on the burden of AD and other dementias provide critical insights for guiding prevention and treatment strategies.
Objective
To estimate the global, regional, and national burden and attributable risk factors of AD and other dementias from 1990 to 2021.
Methods
This cross-sectional study utilized the 2021 Global Burden of Disease (GBD) dataset from 204 countries and territories. The analysis focused on individuals aged 40 years and older with AD and other dementias and included data on incidence, all-cause and cause-specific mortality, disability-adjusted life years (DALYs), and estimated annual percentage changes (EAPCs). These trends were stratified by region, country, age, sex, and Socio-Demographic Index (SDI).
Results
From 1990 to 2021, global DALYs attributable to AD and other dementias rose from 3.83 million to 9.84 million. Age-standardized rates (ASRs) of incidence and DALYs increased for both sexes, with a more pronounced rise in males. ASRs for incidence, prevalence, and DALYs were positively correlated with SDI. Smoking was identified as the primary risk factor for dementia burden among males, whereas obesity was the leading risk factor for females.
Conclusions
The global burden of AD and other dementias has significantly increased from 1990 to 2021, especially in high-SDI regions. While females have a higher overall risk, the burden has grown more rapidly in males. These findings highlight the need for targeted interventions to address aging populations and reduce dementia risk factors.
NicholsEAbd-AllahFAbdoliA, et al.The burden of dementia due to Down syndrome, Parkinson's disease, stroke, and traumatic brain injury: a systematic analysis for the global burden of disease study 2019. Neuroepidemiology2021; 55: 286–296.
2.
CuiMJiangYFZhaoQH, et al.Metabolomics and incident dementia in older Chinese adults: the Shanghai Aging Study. Alzheimers Dement2020; 16: 779–788.
3.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
4.
KawasCHKimRCSonnenJA, et al.Multiple pathologies are common and related to dementia in the oldest-old The 90+Study. Neurology2015; 85: 535–542.
5.
KnopmanDSAmievaHPetersenRC, et al.Alzheimer disease. Nat Rev Dis Primers2021; 7: 33.
6.
EisenmannYGollaHSchmidtH, et al.Palliative care in advanced dementia. Front Psychiatry2020; 11: 699.
7.
WuYTBeiserASBretelerMMB, et al.The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol2017; 13: 327–379.
8.
GaleSAAcarDDaffnerKR. Dementia. Am J Med2018; 131: 1161–1169.
9.
LiJLXiaDCuiM, et al.Disease trajectories before dementia: evidence from a large-scale community-based prospective study. Br J Psychiatry2024; 225: 538–546.
10.
SlotRERSikkesSAMBerkhofJ, et al.Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimers Dement2019; 15: 465–476.
11.
Garre-OlmoJ. Epidemiology of Alzheimer's disease and other dementias. Rev Neurol2018; 66: 377–386.
12.
RazLKnoefelJBhaskarK. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab2016; 36: 172–186.
13.
DingQQLiuSWYaoYD, et al.Global, regional, and national burden of ischemic stroke, 1990-2019. Neurology2022; 98: E279–E290.
14.
ChanKYWangWWuJJ, et al.Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet2013; 381: 2016–2023.
15.
NicholsESzoekeCEIVollsetSE, et al.Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol2019; 18: 88–106.
16.
WangJTXuGRenRJ, et al.The impacts of health insurance and resource on the burden of Alzheimer's disease and related dementias in the world population. Alzheimers Dement2023; 19: 967–979.
17.
LivingstonGHuntleyJLiuKY, et al.Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet2024; 404: 572–628.
18.
VaratharajAThomasNEllulMA, et al.Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry2020; 7: 875–882.
19.
SnyderHMAsthanaSBainL, et al.Sex biology contributions to vulnerability to Alzheimer's disease: a think tank convened by the Women's Alzheimer's Research Initiative. Alzheimers Dement2016; 12: 1186–1196.
20.
JiaLFQuanMNFuY, et al.Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol2020; 19: 81–92.
21.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet2020; 396: 413–446.
22.
LivingstonGSommerladAOrgetaV, et al.Dementia prevention, intervention, and care. Lancet2017; 390: 2673–2734.
23.
CahillS. WHO's global action plan on the public health response to dementia: some challenges and opportunities. Aging Ment Health2020; 24: 197–199.
24.
FerrariAJSantomauroDFAaliA, et al.Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet2024; 403: 2133–2161.
25.
VosT. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet2020; 396: 1562–1562.
26.
WangHAbbasKMAbbasifardM, et al.Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet2020; 396: 1160–1203.
27.
GrassiMRouleauxNCaldirolaD, et al.A novel ensemble-based machine learning algorithm to predict the conversion from mild cognitive impairment to Alzheimer's disease using socio-demographic characteristics, clinical information, and neuropsychological measures. Front Neurol2019; 10: 756.
28.
LinXLXuYFXuJY, et al.Global burden of noncommunicable disease attributable to high body mass index in 195 countries and territories, 1990-2017. Endocrine2020; 69: 310–320.
29.
LiuQQWangHYChenZ, et al.Global, regional, and national epidemiology of nasopharyngeal carcinoma in middle-aged and elderly patients from 1990 to 2021. Ageing Res Rev2025; 104: 102613.
30.
WangYLiangJJFangYT, et al.Burden of common neurologic diseases in Asian countries, 1990-2019 an analysis for the global burden of disease study 2019. Neurology2023; 100: E2141–E2154.
31.
ZhangXYGuoTTZhangY, et al.Global burden of Alzheimer's disease and other dementias attributed to metabolic risks from 1990 to 2021: results from the global burden of disease study 2021. BMC Psychiatry2024; 24: 910.
32.
GaoSYangWSBrayF, et al.Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends in 1976-2005. Eur J Epidemiol2012; 27: 39–46.
33.
MatthewsKAXuWGagliotiAH, et al.Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimers Dement2019; 15: 17–24.
34.
PrinceMBryceRAlbaneseE, et al.The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement2013; 9: 63–75.
JackCRBennettDABlennowK, et al.NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
38.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
39.
NicholsESteinmetzJDVollsetSE, et al.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health2022; 7: E105–E125.
40.
XiaXHZhengWYLJ. COVID-19 and Alzheimer's disease: how one crisis worsens the other. Transl Neurodegener2021; 10: 15.
41.
NianogoRARosenwohl-MackAYaffeK, et al.Risk factors associated with Alzheimer disease and related dementias by sex and race and ethnicity in the US. JAMA Neurol2022; 79: 584–591.
42.
TowerJ. Sex-specific gene expression and life span regulation. Trends Endocrinol Metab2017; 28: 735–747.
43.
ZhuDHMontagneAZhaoZ. Alzheimer's pathogenic mechanisms and underlying sex difference. Cell Mol Life Sci2021; 78: 4907–4920.
44.
RoccaWAMielkeMMVemuriP, et al.Sex and gender differences in the causes of dementia: a narrative review. Maturitas2014; 79: 196–201.
45.
SchwarzKGVicencioSCInestrosaNC, et al.Autonomic nervous system dysfunction throughout menopausal transition: a potential mechanism underpinning cardiovascular and cognitive alterations during female ageing. J Physiol2024; 602: 263–280.
46.
ArdekaniBAConvitABachmanAH. Analysis of the MIRIAD data shows sex differences in hippocampal atrophy progression. J Alzheimers Dis2016; 50: 847–857.
47.
EidRSGobinathARGaleaLAM. Sex differences in depression: insights from clinical and preclinical studies. Prog Neurobiol2019; 176: 86–102.
48.
NgoSTSteynFJMcCombePA. Gender differences in autoimmune disease. Front Neuroendocrinol2014; 35: 347–369.
49.
LiRNSinghM. Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol2014; 35: 385–403.
50.
NebelRAAggarwalNTBarnesLL, et al.Understanding the impact of sex and gender in Alzheimer's disease: a call to action. Alzheimers Dement2018; 14: 1171–1183.
51.
PikeCJ. Sex and the development of Alzheimer's disease. J Neurosci Res2017; 95: 671–680.
52.
PodcasyJLEppersonCN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci2016; 18: 437–446.
53.
ZhaoNRenYXYamazakiY, et al.Alzheimer's risk factors age, APOE genotype, and sex drive distinct molecular pathways. Neuron2020; 106: 727–742.e6.
54.
Serrano-PozoADasSHymanBT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol2021; 20: 68–80.
55.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet2020; 396: 1204–1222.
56.
OrgetaVLeungPDel-Pino-CasadoR, et al.Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev2022; 4: CD009125.
57.
SrivastavaSAhmadRKhareSK. Alzheimer's disease and its treatment by different approaches: a review. Eur J Med Chem2021; 216: 113320.
58.
NakamuraYKitamuraSHommaA, et al.Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opin Pharmacother2014; 15: 913–925.
59.
KishiTMatsunagaSIwataN. Memantine treatment for Japanese patients with moderate to severe Alzheimer's disease: a meta-analysis of double-blind, randomized, placebo-controlled trials. Neuropsychiatr Dis Treat2018; 14: 2915–2922.
60.
OlmastroniEMolariGDe BeniN, et al.Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol2022; 29: 804–814.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
